Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).

Hawton A, Green C, Goodwin E, Harrower T.

Eur J Health Econ. 2019 Aug 13. doi: 10.1007/s10198-019-01092-9. [Epub ahead of print]

PMID:
31410669
2.

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

Lennox B, Yeeles K, Jones PB, Zandi M, Joyce E, Yu LM, Tomei G, Pollard R, Vincent SA, Shimazaki M, Cairns I, Dowling F, Kabir T, Barnes TRE, Lingford Hughes A, Hosseini AA, Harrower T, Buckley C, Coles A.

Trials. 2019 Jun 7;20(1):331. doi: 10.1186/s13063-019-3336-1.

3.

The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease.

Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D, Talbot K, Harrower T, Walsh J, Chandran S, Hanemann CO, Mills R, Tennant A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):317-327. doi: 10.1080/21678421.2019.1615951. Epub 2019 May 22.

PMID:
31116037
4.

Outcome of cell suspension allografts in a patient with Huntington's disease.

Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, Barker RA, Cicchetti F.

Ann Neurol. 2018 Dec;84(6):950-956. doi: 10.1002/ana.25354. Epub 2018 Oct 25.

5.

Validating the portal population of the United Kingdom Multiple Sclerosis Register.

Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV.

Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25.

PMID:
29860199
6.

Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.

Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T, McDermott CJ, Majeed T, Pinto A, Talbot K, Williams T, Young CA; TONiC study group.

Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.

PMID:
29468643
7.

Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.

Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J.

Clinicoecon Outcomes Res. 2017 Apr 15;9:211-229. doi: 10.2147/CEOR.S112254. eCollection 2017.

8.

A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.

McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Malaspina A, Morrison KE, Orrell RW, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):1-9. doi: 10.1080/21678421.2016.1221433. Epub 2016 Aug 31. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):152.

9.

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.

Abogunrin S, Brand S, Desai K, Dinet J, Gabriel S, Harrower T.

Clinicoecon Outcomes Res. 2015 Sep 9;7:441-9. doi: 10.2147/CEOR.S86355. eCollection 2015.

10.

Laboratory medicine best practice guideline: vitamins a, e and the carotenoids in blood.

Greaves RF, Woollard GA, Hoad KE, Walmsley TA, Johnson LA, Briscoe S, Koetsier S, Harrower T, Gill JP.

Clin Biochem Rev. 2014 May;35(2):81-113.

11.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

12.

Management of sialorrhoea in motor neuron disease: a survey of current UK practice.

Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Majeed T, Malaspina A, Morrison K, Orrell RW, Pall H, Pinto A, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):521-7. doi: 10.3109/21678421.2013.790452. Epub 2013 May 7.

PMID:
23647474
13.

Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome.

Alkufri F, Harrower T, Rahman Y, Hughes E, Mundy H, Knibb JA, Moriarty J, Connor S, Samuel M.

Mov Disord. 2013 Mar;28(3):399-401. doi: 10.1002/mds.25276. Epub 2013 Feb 22. No abstract available.

PMID:
23436702
14.

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.

Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB; NEST-UK collaboration.

J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):657-65. doi: 10.1136/jnnp-2012-302441. Epub 2013 Jan 23.

15.

TB or not TB?

Harrower T, O'Donovan D, Bavetta S, Chaudhuri A.

Am J Med. 2008 Aug;121(8):684-6. doi: 10.1016/j.amjmed.2008.01.018. No abstract available.

PMID:
18691479
16.

Stent placement for management of a small parasagittal meningioma. Technical note.

Ganesan D, Higgins JN, Harrower T, Burnet NG, Sarkies NJ, Manford M, Pickard JD.

J Neurosurg. 2008 Feb;108(2):377-81. doi: 10.3171/JNS/2008/108/2/0377.

PMID:
18240939
17.

POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.

Harrower T, Stewart JD, Hudson G, Houlden H, Warner G, O'Donovan DG, Findlay LJ, Taylor RW, De Silva R, Chinnery PF.

Arch Neurol. 2008 Jan;65(1):133-6. doi: 10.1001/archneurol.2007.4.

PMID:
18195151
18.

A case of voltage-gated potassium channel antibody-related limbic encephalitis.

Harrower T, Foltynie T, Kartsounis L, De Silva RN, Hodges JR.

Nat Clin Pract Neurol. 2006 Jun;2(6):339-43; quiz following 343.

PMID:
16932578
19.

Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report.

Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ, Fletcher PC.

Br J Psychiatry. 2006 Aug;189:182-3.

20.

Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease.

Harrower TP, Tyers P, Hooks Y, Barker RA.

Exp Neurol. 2006 Jan;197(1):56-69. Epub 2005 Oct 24.

PMID:
16246328
21.

Lewy bodies in Parkinson's disease: protectors or perpetrators?

Harrower TP, Michell AW, Barker RA.

Exp Neurol. 2005 Sep;195(1):1-6. Review. No abstract available.

PMID:
16023637
22.

Cell therapies for neurological disease--from bench to clinic to bench.

Harrower T, Barker RA.

Expert Opin Biol Ther. 2005 Mar;5(3):289-91.

PMID:
15833067
23.

LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation.

Blakely EL, de Silva R, King A, Schwarzer V, Harrower T, Dawidek G, Turnbull DM, Taylor RW.

Eur J Hum Genet. 2005 May;13(5):623-7.

24.

Is there a future for neural transplantation?

Harrower TP, Barker RA.

BioDrugs. 2004;18(3):141-53. Review.

PMID:
15161332
25.
26.

Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.

Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA.

Xenotransplantation. 2004 Jan;11(1):60-71.

PMID:
14962294
27.

Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.

Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB; NEST-UK.

J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):678-85.

28.

Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue.

Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA.

Neuroreport. 2002 Mar 25;13(4):481-5.

PMID:
11930166
29.

Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells.

Armstrong RJ, Harrower TP, Hurelbrink CB, McLaughin M, Ratcliffe EL, Tyers P, Richards A, Dunnett SB, Rosser AE, Barker RA.

Neuroscience. 2001;106(1):201-16.

PMID:
11564430
30.

Calcium-PS-dependent protein kinase C and surfactant protein A in isolated fetal rabbit type II alveolar cells and surfactant-related material.

Samuels ER, Harrower T, Kahlon S, Oulton MR, MacDonald J, Siauw C, Scott JE.

Pediatr Pulmonol. 1999 Feb;27(2):95-103.

PMID:
10088932

Supplemental Content

Loading ...
Support Center